- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Prostatype Genomics AB: The subscription period in Prostatype Genomics AB's rights issue of units begins today | 97 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 08.07. | Listing of units rights and paid subscription units of Prostatype Genomics AB | 141 | GlobeNewswire | With effect from July 09, 2026, the units rights in Prostatype Genomics AB will be traded on First North Growth Market. Trading will continue up until and including July 20, 2026.
... ► Artikel lesen | |
| 03.07. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.07.2026 | 708 | Xetra Newsboard | Das Instrument OCI US00089H1068 ACS A.DE C.ADR 1/5/EO-,50 EQUITY wird cum Kapitalmassnahme gehandelt am 03.07.2026 und ex Kapitalmassnahme am 06.07.2026 The instrument OCI US00089H1068 ACS A.DE C.ADR... ► Artikel lesen | |
| 22.06. | Prostatype Genomics AB: Bulletin From Annual General Meeting In Prostatype Genomics AB (publ) | 100 | GlobeNewswire (Europe) | The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the "Company") was held on 22 June 2026. Below is a summary of the resolutions adopted. All resolutions were adopted... ► Artikel lesen | |
| PROSTATYPE GENOMICS Aktie jetzt für 0€ handeln | |||||
| 25.05. | Prostatype Genomics AB: Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype in the United States | 317 | GlobeNewswire (Europe) | Prostatype Genomics has been actively engaged in the process regarding Medicare reimbursement for Prostatype® in the United States for some time. The process is currently in an intensive phase and continues... ► Artikel lesen | |
| 19.05. | Prostatype Genomics AB: Prostatype Genomics AB announces the Board of Directors' intention to resolve on a rights issue of units of approximately SEK 47.4 million | 195 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA... ► Artikel lesen | |
| 26.02. | Prostatype Genomics AB: Prostatype Genomics publishes year-end report for 2025 | 362 | GlobeNewswire (Europe) | Prostatype Genomics AB today publishes its year-end report for the full year 2025, including the interim report for the second half of 2025. The full year-end report is attached and can also be downloaded... ► Artikel lesen | |
| 11.11.25 | Prostatype Genomics AB: Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics | 349 | GlobeNewswire (Europe) | Alongside Prostatype Genomics (the "Company") strategic focus on the U.S. market and continued efforts to secure Medicare reimbursement, the Company has continuously invested in research and development... ► Artikel lesen | |
| 26.08.25 | Prostatype Genomics AB: Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype to insurance companies in the USA | 282 | GlobeNewswire (Europe) | Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has reached an important commercial milestone in the USA by immediately starting to bill Prostatype® to several insurance companies. Prostatype®... ► Artikel lesen | |
| 23.07.25 | Prostatype Genomics AB: Prostatype Genomics publishes its interim report for the first half of 2025 | 313 | GlobeNewswire (Europe) | Prostatype Genomics AB today publishes its interim report for the first half of 2025. The full interim report is attached and can also be downloaded from the company's website, www.prostatypegenomics.com.
First... ► Artikel lesen | |
| 22.07.25 | Prostatype Genomics AB: Positive results for Prostatype confirmed in published Spanish multicentre study | 594 | GlobeNewswire (Europe) | Prostatype Genomics announces that previously communicated positive results from a Spanish multicentre study with Prostatype®, have now been confirmed in a scientific journal. The study included 93... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 34,070 | -0,64 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Siemens Healthineers von 55,80 auf 54,30 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. David Adlington passte seine... ► Artikel lesen | |
| ECKERT & ZIEGLER | 14,280 | -1,04 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| MOUNTAIN VALLEY MD | 0,042 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley MD appoints advisers, grants options | ||
| CYTOSORBENTS | 0,356 | +2,89 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | PRINCETON, N.J., May 13, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| MEDARTIS | 94,00 | 0,00 % | Medartis Holding AG: Medartis gewinnt den Swiss Medtech Award 2026 | Medartis Holding AG
/ Schlagwort(e): Sonstiges
Medartis gewinnt den Swiss Medtech Award 2026 10.06.2026 / 11:49 CET/CEST
MEDIENMITTEILUNG
Bern, 10. Juni 2026: Die Medartis Holding... ► Artikel lesen | |
| GESUNDHEITSWELT CHIEMGAU | 10,200 | 0,00 % | EQS-Adhoc: Gesundheitswelt Chiemgau AG: Gesundheitswelt Chiemgau senkt Ergebnisprognose für das Geschäftsjahr 2026 aufgrund von einmaligen Sondereffekten von rund EUR 13,0 Mio. | EQS-Ad-hoc: Gesundheitswelt Chiemgau AG / Schlagwort(e): Prognose / Gesamtjahr
Gesundheitswelt Chiemgau AG senkt Ergebnisprognose für das Geschäftsjahr 2026 aufgrund von... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 69,68 | +0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| BILLIONTOONE | 124,59 | -0,22 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,210 | +0,05 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen | |
| BETA BIONICS | 16,860 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| GENEDX | 62,37 | -0,10 % | Piper Sandler raises GeneDx stock price target on coverage policy | ||
| HEARTFLOW | 25,500 | +0,04 % | Heartflow, Inc.: New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management | ||
| ADAPTHEALTH | 10,190 | 0,00 % | AdaptHealth Flags Material Breach After Threat Actor Accessed Patient Management Systems | ||
| PROCEPT BIOROBOTICS | 19,300 | -0,05 % | PROCEPT BioRobotics to Report Second Quarter 2026 Financial Results on August 4th, 2026 | ||
| PROGYNY | 32,360 | 0,00 % | KeyBanc raises Progyny stock price target on utilization strength |
PROSTATYPE GENOMICS AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,008 Euro und damit -33,87 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROSTATYPE GENOMICS AB finden Sie auf Wallstreet Online.